Fortress Biotech (FBIO) Stock Price, News & Analysis

Company Overview

Fortress Biotech, Inc. is a biopharmaceutical company focused on developing and commercializing medicines for serious and underserved medical conditions. The company operates through a network of subsidiaries and strategic partners, supporting drug discovery, clinical development, regulatory activities and commercialization.

Its research and development activities span areas including oncology, immunology, dermatology, central nervous system disorders and rare diseases. Fortress has used its platform to establish or support subsidiary companies developing therapeutic candidates and commercial products, with programs ranging from early-stage research through late-stage clinical development and marketed medicines.

Founded in 2014, Fortress Biotech serves patients primarily through the United States healthcare market while pursuing opportunities to advance its therapies internationally through licensing and commercial partnerships. Its business model emphasizes building specialized biotechnology companies around individual drug-development programs and therapeutic areas.

Key Stats

• Today's Range: $2.01 to $2.09
• 50-Day Range: $2.03 to $3.39
• 52-Week Range: $2.01 to $4.53
• Volume: 326,464 shs
• Average Volume: 246,765 shs
• Market Capitalization: $67.70 million
• P/E Ratio: 0.77
• Dividend Yield: N/A
• Price Target: $17.00
• Consensus Rating: Hold

Fortress Biotech Stock Analysis - MarketRank™

Fortress Biotech scored higher than 43% of companies evaluated by MarketBeat, and ranked 554th out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Hold

Consensus Rating

Fortress Biotech has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Fortress Biotech has a consensus price target of $17.00, representing about 737.4% upside from its current price of $2.03.

Amount of Analyst Coverage

Fortress Biotech has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Fortress Biotech is 0.77, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.66.

Price to Earnings Ratio vs. Sector

The P/E ratio of Fortress Biotech is 0.77, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.67.

Price to Book Value per Share Ratio

Fortress Biotech has a P/B Ratio of 1.02. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

21.42% of the float of Fortress Biotech has been sold short.

Short Interest Ratio / Days to Cover

Fortress Biotech has a short interest ratio ("days to cover") of 18.97, which indicates bearish sentiment.

Change versus previous month

Short interest in Fortress Biotech has recently decreased by 6.18%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Fortress Biotech does not currently pay a dividend.

Dividend Growth

Fortress Biotech does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Fortress Biotech this week, compared to 2 articles on an average week.

Search Interest

Only 5 people have searched for FBIO on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.

MarketBeat Follows

1 people have added Fortress Biotech to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Fortress Biotech insiders have not sold or bought any company stock.

Percentage Held by Insiders

28.50% of the stock of Fortress Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

96.51% of the stock of Fortress Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/03/2026
• Next Earnings (Estimated): 11/16/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:FBIO
• CIK: 1429260
• Web: www.fortressbiotech.com
• Phone: (781) 652-4500
• Fax: 781-652-4545
• Employees: 78
• Year Founded: 2006

Price Target and Rating

• Average Price Target for Fortress Biotech: $17.00
• High Price Target: $17.00
• Low Price Target: $17.00
• Potential Upside/Downside: +737.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.64
• Trailing P/E Ratio: 0.77
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $6.82 million
• Net Margins: 163.32%
• Pretax Margin: 213.28%
• Return on Equity: 83.47%
• Return on Assets: 42.98%

Debt

• Debt-to-Equity Ratio: 0.17
• Current Ratio: 3.96
• Quick Ratio: 3.83

Sales & Book Value

• Annual Sales: $63.26 million
• Price / Sales: 1.07
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.00 per share
• Price / Book: 1.02

Miscellaneous

• Outstanding Shares: 33,350,000
• Free Float: 23,846,000
• Market Cap: $67.70 million
• Optionable: Optionable
• Beta: 1.25